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Datafromstudieswithhumanshavesuggestedthatabnormalitiesofmidbrainstructures,includingtheperiaqueductalgraymatter
(PAG), could be involved in the neurobiology of panic disorder (PD). The electrical stimulation of the PAG in neurosurgical
patients induces panic-like symptoms and the eﬀect of drugs that are eﬀective in the treatment of PD in the simulation of public
speaking model of anxiety is in agreement with data from animal models of PD. Structural neuroimaging studies have shown
increases in gray matter volume of midbrain and pons of PD patients. There is also evidence of lower serotonin transporter and
receptor binding, and increases of metabolism in the midbrain of PD patients. Nevertheless, these midbrain abnormalities can not
be considered as speciﬁc ﬁndings, since neuroimaging data indicate that PD patients have abnormalities in other brain structures
that process fear and anxiety.
Copyright © 2009 C. M. Del-Ben and F. G. Graeﬀ. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Panic disorder (PD) is a common and incapacitating mental
disorder characterized by the recurrence of spontaneous
panic attacks, followed by a persistent concern about having
additional attacks, worry about the implications of the attack
or its consequences, and a signiﬁcant change in the behavior
related to the attacks. A panic attack is characterized as
a discrete period of intense fear or discomfort, in which
several symptoms, such as palpitations, pounding heart,
or accelerated heart rate; sweating; trembling or shaking;
sensations of shortness of breath or smothering; feeling
of choking; chest pain or discomfort; nausea or abdomi-
nal distress; feeling dizzy, unsteady, lightheaded, or faint;
derealization or depersonalization; fear of losing control or
going crazy; fear of dying; paresthesias; chills or hot ﬂushes,
develop abruptly and reach a peak within 10 minutes. The
symptoms are not related to substance abuse or general
medical condition and are associated with a signiﬁcant
impairment of global functioning. Around 2/3 of patients
withPDwillalsodevelopagoraphobia,whichisdeﬁnedasan
anxietyaboutbeinginplacesorsituationsfromwhichescape
might be diﬃcult, or embarrassing; or in whichhelp may not
be available in the event of an unexpected or situationally
predisposed panic attack. Agoraphobic fearstypically involve
characteristic clusters of situations that include being outside
the home alone, being in a crowd or standing in a line, being
on a bridge, and traveling in a bus, train, or automobile [1].
Several brain structures that organize defensive reactions
and represent the neural substrate of fear and anxiety have
been implicated in the functional neuroanatomy of PD.
Among those are prefrontal regions, amygdala, hippocam-
pus, and parahippocampal area, hypothalamus, thalamus,
and the periaqueductal grey matter (PAG) (for a recent
review; see [2]). In regard to the latter region, animal studies
have shown that electrical and chemical stimulations of the
PAG cause urgent defensive reactions, such as freezing, ﬁght,
or ﬂight. The same responses occur when the animal is
faced by a clear and near threat, for instance, a predator
[3]. Therefore, the PAG has been implicated in the defensive
reaction to proximal threats, and drugs that increase the
serotonergic function and are eﬀective in the treatment of
P Da r ea b l et or e d u c eb e h a v i o r sn o r m a l l yo b s e r v e dw i t h
the stimulation of the PAG (reviewed in [4]). Although
other neurotransmitters, such as cholecystokinin [5]a n d
glutamate [6], also appear to regulate fear/panic-related2 Neural Plasticity
defensive behavior, the main focus of this review will be on
serotonin (5-HT) since this is the main neurotransmitter
aﬀected by the drugs clinically used for the treatment of
PD.
Even though the evidence that supports the involvement
of the neurocircuitry underlying defensive reactions in
normal and pathological fear and anxiety has mainly been
obtained with preclinical research, data from studies with
humans also give support to the concept that structural and
functional abnormalities in midbrain structures, such as the
PAG, could be involved in the neurobiology of PD. Several
reviews (e.g., [2]) have brought together animal ﬁndings
showing the role of PAG in fear reactions and defensive
behavior to proximal threats, but data coming from studies
with human beings have not been completely explored.
Therefore, the focus of this review is on results from human
studies, including healthy volunteers and patients with PD,
which provide evidence for a participation of the PAG in the
pathophysiology of PD.
2.SymptomaticHomology
A pivotal evidence for the involvement of midbrain struc-
tures in PD came from the induction of panic-like symptoms
byelectricalstimulationofthePAGinneurosurgicalpatients.
Awaked patients submitted to the stimulation of the PAG
report feelings of terror or impending death, desire to
ﬂee, palpitation, and respiratory arrest or hyperventilation
[7–9]. The remarkable similarities between the eﬀects of
PAG electrical stimulation in neurosurgical patients reported
above and the symptoms that occur during a panic attack
led the Brazilian psychiatrist Valentil Gentil to suggest a
participationofthePAGintheneurobiologyofpanicattacks.
Commenting on the changing in the behavior of rats due
to the stimulation of the dorsal PAG, Gentil remarked,
“I believe that (this animal) model is particularly useful
for the understanding of the pathophysiology of panic
attacks, especially the “spontaneous” attacks. ... (Bearing
in mind that) the panic attack is a very primitive behavior
... the isomorphic validity of the central gray’s (PAG)
poorly organized responses to γ-aminobutyric acid (GABA-
A) antagonists and electrical stimulation to the maladaptive
ﬂightbehavioroffull-blownpanicseemshigh”[10].Further,
the phenomenological resemblance between panic attacks
and the eﬀects of the electrical stimulation of the PAG in
both humans and animals has been systematically explored
[11, 12], the main results being summarized in Table 1.
Although the similarity between the symptoms of a
spontaneous panic attack and the eﬀects of electrical stim-
ulation of PAG is often cited as a face-validity criterion
for implicating the PAG in PD, information obtained from
awaked patients about the subjective and somatic responses
provoked by stimulation of PAG is rare in the recent
literature. An exception is the work carried out by Green
et al. [13], using deep brain stimulation, who have obtained
results similar to those reported by Nashold et al. [7], four
decades ago. In the procedure of deep brain stimulation,
electrodes are implanted permanently into speciﬁc areas of
the brain. The electrodes are connected by wires under the
skintoageneratorallowingcontinuouselectricalstimulation
of speciﬁc brain areas. In this study, patients had electrodes
implanted inside the PAG to control neuropathic pain. It
has been observed that electrodes placed more dorsally
in the PAG increased systolic and diastolic arterial blood
pressure, what did not occur with electrodes placed more
ventrally in the PAG. Moreover, two patients with dorsal
electrodes reported nausea, sweating, and anxiety, symptoms
commonly observed during a spontaneous panic attack.
Although this issue has not been completely established,
there is some evidence pointing to an association between
PD and hypertension. In this regard, it has been proposed
that both conditions would share a dysfunction of brainstem
structures that regulate the autonomic nervous system and
are inhibited by 5-HT [14].
3.ExperimentalAnxietyinHumans
Aiming to conciliate seemingly conﬂicting results derived
from animal studies about the role of 5-HT in anxiety, it
has been proposed that 5-HT projections from the dorsal
raphe nucleus (DRN) facilitate inhibitory avoidance in
limbic forebrain structures, predominantly amygdala and
frontal cortex, while inhibit escape in the dorsal PAG [12].
This arrangement may have adaptive value, since it allows
inhibition of ﬁght/ﬂight behavior in situations where threat
is only potential or remote.
More recently, Lowry et al. [15] have shown that the
5-HT projections to cortical and limbic structures arise
from a neuronal set located in a speciﬁc part of the caudal
DRN, which is particularly sensitive to stressful stimuli. The
rostral projections from these neurons seem to constitute
a mesocorticolimbic 5-HT system that modulates defense.
Based on correlations between the pharmacological eﬃcacy
of antidepressants and anxiolytic drugs in anxiety disorders
andtheresultsobtainedinexperimentalmodelsofanxietyin
humans (discussed below), it has been further suggested that
generalized anxiety disorder (GAD) would be related to the
inhibitory avoidance and conditioned anxiety, whereas PD
would be related to the escape response and innate fear [16].
Aschematicrepresentationofthehypothesisonthedualrole
of 5-HT in anxiety and defense is represented in Figure 1.
This theoretical model has been systematically tested
using two experimental procedures that generate anxiety
in human beings: the simulated public speaking (SPS) and
the skin conductance response (CSCR) tests (for a review;
see [17]). It is important to note that this experimental
approach is diﬀerent from that used in pharmacological
challenges aimed at provoking a panic attack in vulnerable
individuals. In this case, the most used are the infusion of
sodium lactate and the inhalation of CO2. Both challenges
induce panic attacks in around 60 to 80% of panic patients,
as compared to 0 to 20% of healthy controls. This seems
to be a very speciﬁc response, since these challenges do
not cause panic attacks in phobic or obsessive compulsive
patients. Moreover, pharmacological studies have evidenced
that antidepressant treatment decreases the vulnerability ofNeural Plasticity 3
Table 1: Phenomenological similarities between panic attacks and eﬀects of electrical stimulation of the periaqueductal gray matter (PAG)
in humans and rats. Adapted from Jenck et al. [11] and Schenberg et al. [12].
Spontaneous panic attack Stimulation of dorsal PAG in humans Stimulation of dorsal PAG in rats
Intense fear or discomfort Panic, terror —
— Intense distress Aversion
Palpitations, pounding heart, or accelerated heart rate Tachycardia Tachycardia
Sweating Sweating —
Trembling or shaking Sensation of vibration —
Sensations of shortness of breath or smothering — Tachypnea
— Hyperventilation Hyperventilation
—A p n e a —
Chest pain or discomfort Chest and heart pain —
Nausea or abdominal distress Bladder voiding urge Micturation
—— D e f e c a t i o n
Fear of dying “Scared to death” Escape responses
Chills or hot ﬂushes “Burn/cold” sensations —
Threat
Amygdala
Escape
anxiety
PAG
DRN
Fight
panic
−
+
Figure 1: Schematic representation of the dual role of serotonin on
fear and anxiety, according to Deakin and Graeﬀ theory.
panic patients to lactate and/or CO2 [18]. The similarities
between the eﬀects of lactate and CO2 led to the hypothesis
that both challenges have a common mechanism of action,
causing an intraneuronal hypercapnia in brain areas that are
stimulatedbyCO2 duringsuﬀocation.Thesensitivityofsuch
suﬀocationalarmsystemwouldbeabnormallyheightenedin
PD patients [19].
Basically, the SPS test consists in the preparation and
performance of a speech in front of a videocamera, with
the participant seeing his/her own image on a TV screen.
Subjective and physiologic measures of anxiety are taken
before, during and after the speech. The emotional state
induced by SPS is supposed to be species-speciﬁc fear, given
that fear of speaking is highly prevalent in the general
population [20] and occurs in healthy persons, irrespective
of their personality trait to react with more or less anxiety to
stressfulsituations[21].Pharmacologicalstudieshaveshown
that drugs that facilitate 5-HT function decrease, whereas
drugs that impair 5-HT function increase speaking fear [17].
On the other hand, the CSCR test is based on classical
conditioning theory, consisting in the presentation of 10
neutral tones (habituation phase), followed by a neutral tone
paired with a loud white noise (acquisition phase) and by the
representationof10neutraltones(extinctionphase).During
the procedures, measures of skin conductance are taken.
Drugsthatincrease5-HTtendtofacilitateconditioning[17].
Several 5-HT acting drugs have been assayed in these
tests. For instance, a single dose of chlomipramine [22]
and nefazodone [23] administered to healthy volunteers
increased the fear provoked by the SPS, and this eﬀect
has been related to the clinical worsening observed at the
beginning of the treatment with antidepressants [24–26].
Whilesomeanimalstudieshaveshownanincreaseincortical
extracellular level of 5-HT following acute administration
of antidepressants [27–29], others have shown a greater
increase of extracellular 5-HT in the raphe nuclei than in
the neocortex [30]. If so, a single dose of an antidepressant
would preferentially increase the concentration of 5-HT near
the cell bodies of serotonergic neurons, which would activate
somatodendritic 5-HT1A autoreceptors, reducing neuronal
ﬁring [31] and, consequently, leading to a decrease in the
release of 5-HT in the synaptic cleft. Therefore, the fear-
enhancing eﬀect of a single dose of antidepressants in SPS
could be due to a lack of 5-HT inhibition of brain systems
that generate panic attacks, likely to be localized in the dorsal
PAG [4, 32].
In agreement with the hypothesis about the dual role
of 5-HT in fear and anxiety, ritanserin, a 5-HT receptor
antagonist, has shown opposite eﬀects in the SPS and CSCR
tests, prolonging the fear induced by SPS and decreasing
conditioned skin conductance responses [33]. These results
resemble reported clinical results with ritanserin, showing
improvement of GAD [34], but a tendency to aggravate PD
[35, 36]. To the opposite direction, the 5-HT releaser d-
fenﬂuramine has been shown to reduce SPS-induced fear
[37] and to improve PD [38, 39]. In contrast, d-fenﬂuramine
tended to increase the amplitude of conditioned skin con-
ductanceresponses,suggestingananxiogenic-likeeﬀect[37].4 Neural Plasticity
Hence these pharmacological results with experimen-
tally-induced fear and anxiety in humans are in agreement
with the hypothesis that 5-HT enhances anxiety, which can
be evaluated by the CSCR test, whereas inhibits fear, which
can be assessed by the SPS test. The former eﬀect would
be related to the action of 5-HT on forebrain structures
and the latter to its action on dorsal PAG. It has been well
demonstrated that the chronic use of drugs that increase
the availability of serotonin in the synaptic cleft is eﬀective
for the treatment of PD [40] and it has been proposed that
the reduction in the occurrence of panic attacks with the
use of antidepressants could be due to enhancement of the
inhibitory action of serotonin on the PAG [4].
4. PanicPatients andExperimental
Models of Anxiety
It is important to note that the SPS is not taken as a model of
panic attack and it is not expected to provoke panic attacks
in susceptible individuals. The possible association between
the experimental model and the mental disorder is based on
the rationale that public speaking would engage the neural
substratesinvolved in the process of innate fear, which would
be abnormal in PD.
Therefore, if the predictions derived from pharmacolog-
ical studies with the human tests discussed above are correct,
it would be expected that patients with the diagnosis of PD
and healthy volunteers would perform diﬀerently in the SPS,
but not in the CSCR test, given that the former would engage
the brain mechanisms implicated in the neurobiology of PD,
but the latter would not.
Aiming to test this hypothesis, we submitted panic
patients free of treatment to both models of anxiety [41].
As predicted, controls and panic patients showed a similar
response to CSCR. In contrast, during the SPS test, panic
patients demonstrated higher levels of subjective anxiety
than healthy volunteers from the beginning to the end of the
experimental session but were less responsive to the speaking
challenge. The proﬁle of the subjective response of panic
patients to the SPS test bears a resemblance to the eﬀect
of metergoline, a nonselective 5-HT-receptor blocker, given
to healthy volunteers. Metergoline enhanced the subjective
anxiety before and after the speech, but not during the
preparation or the performance of the speech [42]. These
results were in agreement with the suggestion that an
impairment of the 5-HT function leading to a reduced of the
inhibition of PAG may be present in the neurobiology of PD
[16].
Using a similar protocol [43, 44], new groups of
symptomatic panic patients and healthy controls were
submitted to the SPS test. In addition, a third experimen-
tal group composed by panic patients who had become
nonsymptomatic after long-term pharmacological treatment
with antidepressant drugs was added. The aim was to
verify whether the diﬀerences between healthy subjects and
PD patients, if replicated, would remain after recovery,
being thus related to a vulnerability trait, or otherwise
decrease, and therefore being related to the clinical condition
(state).
A sc a nb es e e ni nFigure 2, and in agreement with the
former study, symptomatic drug free panic patients had
moresubjectiveanxietyduringtheexperimentalsessionthan
controls, despite the changes introduced in the procedures
to minimize diﬀerences in expectancy and familiarity that
might enhance or decrease initial anxiety, respectively. A
more prolonged period of habituation decreased the anxiety
in all groups, but the response to the SPS challenge was
smaller in symptomatic patients than in normal controls.
Moreover, nonsymptomatic patients stand between controls
(below) and symptomatic panic patients (above) with regard
to subjective anxiety, measured by the visual analogue mood
scale(VAMS)andtobodilysymptoms,measuredbythetotal
score of the bodily symptoms scale (BSS). Therefore, these
measures seem to be related to the magnitude of clinical
manifestationsofPDratherthantoavulnerabilitytrait,since
they were aﬀected by pharmacological treatment.
This study has also shown a signiﬁcant decrease in the
level of salivary cortisol from the initial to the pretest phases
of the experimental session, in parallel with habituation
of the anticipatory anxiety induced by the experimental
setting. Additionally, a positive correlation between levels of
subjective anxiety and of salivary cortisol has been found
in control subjects at the initial phase of the experimental
session. In contrast, salivary cortisol did not increase during
the 60 minutes following the end of the speech, neither
in patients, nor in controls, despite the levels of anxiety
measured during speech preparation and performance being
at least as high as those at the onset of the experimental
session. Therefore, the SPS task does not seem to increase
cortisol secretion. In agreement with these results, neither
spontaneous panic attacks [45] nor the electrical stimulation
of the dorsal PAG of the rat [46] activates the hypothalamic-
pituitary-adrenal axis.
A ﬁnalremarkabout thepossible abnormal processing of
innate fear in PD has come from a study carried out in our
laboratory with patients with social anxiety disorder (SAD)
submitted to the SPS test (MC Freitas, A Santos Filho, F
Os´ orio, SR Loureiro, CM Del-Ben, AW Zuardi, FG Graeﬀ,
JAS Crippa, unpublished results). SAD and PD are diﬀerent
anxiety disorders, but they keep some similarities, such
as the response to the treatment with antidepressants that
act on 5-HT function. However, in comparison to healthy
controls, SAD patients have shown a larger enhancement
of the fear induced by the SPS, what is diﬀerent from the
results obtained with PD patients. For that reason, we could
speculate that the lower fear response induced by SPS could
be speciﬁc to PD and related to abnormal functioning of
brain structures involved in the process of innate fear.
5.NeuroimagingData
As discussed earlier, evidence from preclinical studies sug-
gests that the neural substrates involved in the defensive
reactions to environmental threats of mammalian species
could be implicated in the pathophysiology of PD. The mainNeural Plasticity 5
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Figure 2:Changesinanxiety(VAMS,upperpanel),bodilysymptoms(BSS,mildpanel),andsalivarycortisollevels(lowerpanel)inducedby
simulated public speaking (SPS) in symptomatic panic patients (SPD), nonsymptomatic patients (NSPD), and healthy controls. The phases
of the experimental session are beginning (B), pretest (P), anxiety during speech preparation (A), performance anxiety during the speech
(S), and ﬁnal (F). Points in the curves indicate mean values and vertical bars the S.E.M. Figure modiﬁed from Garcia-Leal et al. [43]a n d
Parente et al. [44]. ∗ = signiﬁcant diﬀerence (P<. 05) from controls.
brain structures possibly involved in the neurobiology of PD
encompass the prefrontal cortex, anterior cingulated cortex,
hypothalamus, amygdala, hippocampus, and the midbrain,
including the periaqueductal grey matter [2].
Structural neuroimaging studies, using magnetic reso-
nance imaging (MRI), have shown that anatomical brain
abnormalities, particularly in the temporal lobes, are more
frequently observed in panic patients than in controls [47–
49]. A quantitative evaluation of speciﬁc brain structures
has also demonstrated diﬀerences between PD patients and
healthy volunteers, characterized by a reduction of the
volume of temporal lobes, amygdala, and hippocampus
(trend) in PD patients compared to controls [50–52].
Voxel-based morphometry (VBM) is a more sophisti-
cated approach of structural neuroimaging that provides an
automated method of segmentation into gray matter, white
matter, and cerebrospinal ﬂuid (CSF) compartments and
allows the investigation of diﬀerences in regional volumes
along the whole brain [53]. Using the VBM technique,
Protopopescu et al. [54] have shown an increase in gray
matter volume of the midbrain and rostral pons of the
brainstem of panic patients compared with healthy controls.
At a lower signiﬁcance threshold, they have also reported
increased ventral hippocampal and decreased regional pre-
frontal cortex volumes in PD.
In a recently published study [55], we have also found a
relative increase in gray matter volume of midbrain and pons
(on left) in panic patients. As it can be seen in the Figure 3,
additional ﬁndings include increase in gray matter volume of
the left insula and left superior temporal gyrus and a relative
gray matter decrease in the right anterior cingulate cortex.
The anterior insula has close connections to the amygdala
and, together with the ventromedial prefrontal cortex, ante-
rior cingulate cortex,hypothalamus, and periaqueductal gray6 Neural Plasticity
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Figure 3: Statistical parametric maps displaying signiﬁcant diﬀerences in gray matter volume of PD patients (n = 19) relative to healthy
controls (n = 20). (a) Increased gray matter volume, (b) decreased gray matter volume. 1 = left insula; 2 = left superior temporal gyrus;
3 = midbrain; 4 = right anterior cingulate.
matter, is considered as part of a network that modulates the
identiﬁcation of, and the response to, aversive or threatening
stimuli [56] and has been proposed as a key structure
involved in the neurobiology of anxiety disorders [57]. In
particular, the increase of gray matter volume of midbrain is
in agreement with the proposition that periaqueductal gray
matter would be implicated in the pathophysiology of PD as
wellintheantipanicactionofantidepressantdrugs[2,4,16].
Functional neuroimaging studies have also contributed
to a deeper understanding of the neural substrates of PD.
In a seminal work, using positron emission tomography
(PET), Reiman et al. [58] have found abnormalities in
the parahippocampal gyri, characterized by an abnormal
asymmetry (left less than right) of the regional cerebral
blood ﬂow (rCBF), observed, during rest, in panic patients
vulnerabletothelactatechallenge.Furtherfunctionalstudies
have also shown alterations in the metabolism or blood
ﬂow of hippocampus and parahippocampal areas of panic
patients [59–65] and this seems to be the most consistent
ﬁnding across the studies with functional neuroimaging
in PD. Other areas implicated in the pathology of PD by
functional studies are prefrontal cortex [59, 60, 65], anterior
cingulate gyrus [62, 65], superior temporal cortex [61, 62],
amygdala [63, 64], hypothalamus [62], and thalamus [63,
64].
Considering that the PAG is a small brain structure, the
detection of dysfunctions of its metabolism is not straight-
forward, due to limitations of the neuroimaging technique
itself. Even so, some studies have reported abnormalities in
the midbrain of panic patients.
Just before being submitted to a pentagastrin challenge,
panic patients, compared with healthy volunteers, have
shown an increase of blood ﬂow in parahippocampal
gyrus, left hippocampus, right temporal lobe, orbitofrontal
cortex, anterior cingulate gyrus, hypothalamus, thalamus,
and midbrain, “probably” PAG [62]. Interestingly, bilateral
insula, inferior frontal gyrus, and right amygdala have
shown abnormalities in their metabolism in the opposite
direction, with a decrease of blood ﬂow, what suggests
that the inhibitory function of forebrain structures over
phylogenetically more primitive structures, such as the PAG,
would be impaired in panic patients.
In the same direction, Sakai et al. [63, 64]h a v ef o u n d
higher levels of glucose uptake in the midbrain, caudal pons,
and medulla in panic patients than controls. They also have
shown an increase of the metabolism in bilateral amygdala,
hippocampus, and thalamus. In a further study, the same
group [65] has shown a decrease of glucose uptake in the
right hippocampus, left anterior cingulate, left cerebellum,
and pons and an increase of glucose uptake in bilateral
medial prefrontal cortices in panic patients that had shown
clinical improvement after a cognitive-behavioral therapy
intervention. These changes in the brain metabolism with
the treatment with antidepressants or cognitive-behavioral
therapy have not been found in previous studies [60, 66].
More interestingly for this review is the fact that they have
demonstrated a correlation between the percent changes in
glucose utilization in the midbrain “around PAG” and those
of the number of panic attacks during the 4-week period
before each scan, which shows a direct relation between PAG
metabolism and the occurrence of panic attacks.
Asdiscussedabove,serotoninhasbeenlargelyimplicated
in the pathophysiology of panic disorder, and some evidence
from neuroimaging studies suggests alterations in the 5-
HT system of PD patients. The intravenous administration
of d-fenﬂuramine, which induces the neuronal release of
serotonin, has provoked a decrease of blood ﬂow in the
left posterior parietal-superior temporal cortex in panic
patients [66]. A lower volume of distribution of a selective
radioligand of serotonergic receptors 5-TH1A type has been
described in the anterior cingulate, posterior cingulate, and
raphe of nonmedicated panic patients relative to controls
[67]. A signiﬁcant decrease in the serotonin transporter (5-
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of symptomatic panic patients free of medication has also
been reported [68]. However, in comparison to patients
with current symptoms, panic patients in remission and
free of medication have normal 5-HTT binding properties
in the midbrain and in the temporal regions but still show
signiﬁcantly lower thalamic 5-HTT binding. Considering all
the patients’ (current and in remission) signiﬁcant negative
correlations between the severity of panic symptoms and the
midbrain, temporal lobe, but not thalamic 5-HTT binding,
has also been demonstrated [68].
These abnormalities in the binding of 5-HT receptors
and transporter in midbrain areas are in agreement with
the hypothesis that the occurrence of panic attacks would
be caused by spontaneous activations of the ﬁght/ﬂight
response organized by the PAG and inhibited by 5-HT [16].
Although few studies have applied functional magnetic
resonance imaging (fMRI) in panic patients so far, most
of them conﬁrmed alterations in the brain areas previously
supposed to be involved in the neurocircuitary of PD. In
a paradigm of mental imagery of neutral, moderate, and
high anxiety situations, panic patients have shown increased
neuronal activation in the inferior frontal cortex, hip-
pocampus, and anterior and posterior cingulate, extending
into the orbitofrontal cortex bilaterally, during the anxious
blocks compared to neutral blocks [69]. Panic patients have
also shown signiﬁcantly higher activation in left posterior
cingulate and left middle frontal cortices and a more
pronounced asymmetry (right > left) in parahippocampal
regionsinresponsetoathreat-relatedstimuli,incomparison
to healthy volunteers [70]. Compared to healthy controls,
panicpatientshavedemonstratedsigniﬁcantlylessactivation
to fearful faces in the cingulate cortex and the amygdala,
bilaterally [71].
For our knowledge, none of these fMRI studies have
reported functional alterations in the midbrain. This not
only can be due to limitations of the technique itself that
do not allow the analysis of changes of fMRI signal in
such a small area but also can be related to the hypotheses
underlying the studies, which drive the choice of the
paradigm of psychological activation and determine the
regions of interest where the possible alterations will be
looked for. For instance, in the light of the comprehensive
view of the neurobiology of anxiety and fear proposed by
DeakininGraeﬀ[16]asuitableparadigmtoprovokeenough
haemodinamic response of midbrain areas would be related
to the process of innate fear in humans.
In this regard, a very interesting work carried out with
healthy volunteers has brought some light to this discussion.
Mobbs et al. [72] have evaluated the eﬀects on brain
activation of the distance of a virtual predator. In this
paradigm, participants could control the movements of a
virtual prey (represented as a dot) in a labyrinth presented
on a video-screen, using a keyboard, aiming to avoid a
virtual predator (represented by a triangle) with the ability
to chase, capture, and inﬂict pain. In the case of the predator
caught the prey, two levels of pain represented by either one
or three electric shocks administered to one ﬁnger of the
participant. When the predator was far from the prey, the
haemodinamic responses observed in the prefrontal cortex
and lateral amygdala were more pronounced, particularly
whentheexpectedshockintensitywaslow.Incontrast,when
the predator was closer, the haemodinamic response shifted
to the central amygdala and the PAG, reaching the maximum
of activation when the highest level of pain was anticipated.
Even more interesting, there was a positive correlation
betweenPAGactivationandthereportedsubjectivedegreeof
dread and decreased conﬁdence of escape. These results give
strong support to the role of the midbrain PAG in proximal
defense, and possibly panic, as early proposed [2, 14].
6. Conclusions
In accordance to results coming from animal research, data
from experimental models of anxiety, pharmacological chal-
lenges, and neuroimaging studies carried out with healthy
volunteers and patients with PD point to the involvement
of the PAG in the neurobiology of PD. Nevertheless, these
midbrain abnormalities cannot be considered as speciﬁc
ﬁndings, since neuroimaging data have also shown that
PD patients have changes in other brain structures that
participate in the regulation of fear and anxiety. In a more
integrative approach, it is reasonable to suppose that a
d y s f u n c t i o no fP A Gc o u l db ep a r to fag l o b a ld y s f u n c t i o n
that aﬀects a network of related brain structures, or even
a consequence of other dysfunctions, such as low 5-HT
function, impairment of inhibitory eﬀerent pathways from
rostral brain areas, or both. Further studies conciliating bio-
logical vulnerability, environmental inﬂuences and, mainly,
theconnectivityamongdiﬀerentbrainstructureswithaclear
hypothesis-driven approach are needed.
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